Table IV.

Multivariate analysis for PFS and OS in patients with diffuse large B cell lymphoma patients.

	PFS			OS
Variable	HR	95% CI	P-value	HR	95% CI	P-value
Age, ≤60/>60 years	1.529	0.586–3.984	0.385	1.432	0.428–4.797	0.560
Sex, M/F	0.908	0.443–1.859	0.791	0.521	0.192–1.415	0.201
LDH, ≤200/>200 U/l	0.583	0.256–1.330	0.200	0.405	0.140–1.171	0.095
B symptom, yes/no	1.081	0.451–2.591	0.861	1.077	0.373–3.108	0.890
Stage, I–II/III–IV	2.130	0.922–4.922	0.077	2.043	0.784–5.320	0.144
IPI, 0–2/3–4	0.719	0.333–1.550	0.400	0.311	0.113–0.856	0.024a
ENE, yes/no	0.979	0.473–2.027	0.954	0.877	0.441–2.611	0.877
LMP1, positive/negative	0.165	0.063–0.435	<0.001c	0.208	0.064–0.673	0.009b
miR-155, ≤12/>12 fold high expression	0.415	0.193–0.891	0.024a	0.445	0.174–1.136	0.090

^aP<0.05

^bP<0.01

^cP<0.001. CI, confidence interval; ENE, extranodal extension; HR, hazard ratio; IPI, international prognostic factors index; LDH, lactate dehydrogenase; LMP1, latent membrane protein 1; miR, microRNA; OS, overall survival; PFS, progression-free survival.